These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25761480)

  • 1. Clinical Benefit of Hepatic Arterial Infusion Concurrent Chemoradiotherapy in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Yoon HI; Song KJ; Lee IJ; Kim DY; Han KH; Seong J
    Cancer Res Treat; 2016 Jan; 48(1):190-7. PubMed ID: 25761480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Song JE; Jung KS; Kim DY; Song K; Won JY; Lee HW; Kim BK; Kim SU; Park JY; Ahn SH; Seong J; Han KH
    Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):396-406. PubMed ID: 28871990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma.
    Byun HK; Kim HJ; Im YR; Kim DY; Han KH; Seong J
    Radiother Oncol; 2019 Apr; 133():1-8. PubMed ID: 30935563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Significance of ¹⁸F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study.
    Lee JW; Oh JK; Chung YA; Na SJ; Hyun SH; Hong IK; Eo JS; Song BI; Kim TS; Kim DY; Kim SU; Moon DH; Lee JD; Yun M
    J Nucl Med; 2016 Apr; 57(4):509-16. PubMed ID: 26742711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study.
    Kim JK; Kim JW; Lee IJ; Joo SM; Lee KH; Cho ES; Yu JS; Jeon TJ; Kim Y; Lee JI; Lee KS
    Radiat Oncol; 2017 Aug; 12(1):133. PubMed ID: 28810886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial.
    Kim BK; Kim DY; Byun HK; Choi HJ; Beom SH; Lee HW; Kim SU; Park JY; Ahn SH; Seong J; Han KH
    Int J Radiat Oncol Biol Phys; 2020 May; 107(1):106-115. PubMed ID: 32084526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical resection after down-staging of locally advanced hepatocellular carcinoma by localized concurrent chemoradiotherapy.
    Lee HS; Choi GH; Choi JS; Kim KS; Han KH; Seong J; Ahn SH; Kim DY; Park JY; Kim SU; Kim BK
    Ann Surg Oncol; 2014 Oct; 21(11):3646-53. PubMed ID: 24916746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-confined hepatocellular carcinoma.
    Cha H; Yoon HI; Lee IJ; Koom WS; Han KH; Seong J
    J Radiat Res; 2013 Nov; 54(6):1069-77. PubMed ID: 23633620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downstaging with Localized Concurrent Chemoradiotherapy Can Identify Optimal Surgical Candidates in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
    Chong JU; Choi GH; Han DH; Kim KS; Seong J; Han KH; Choi JS
    Ann Surg Oncol; 2018 Oct; 25(11):3308-3315. PubMed ID: 30083834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
    Han S; Choi HJ; Beom SH; Kim HR; Lee H; Lee JS; Lee HW; Park JY; Kim SU; Kim DY; Ahn SH; Han KH; Seong J; Won JY; Kim BK
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):3123-3133. PubMed ID: 33893539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma: A multicenter study from Japan.
    Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Itobayashi E; Nouso K; Kariyama K; Ishikawa T; Hirooka M; Hiasa Y
    Cancer Sci; 2017 Jul; 108(7):1414-1420. PubMed ID: 28406546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy.
    Han DH; Joo DJ; Kim MS; Choi GH; Choi JS; Park YN; Seong J; Han KH; Kim SI
    Yonsei Med J; 2016 Sep; 57(5):1276-81. PubMed ID: 27401662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
    Kim BK; Ahn SH; Seong JS; Park JY; Kim DY; Kim JK; Lee DY; Lee KH; Han KH
    Liver Int; 2011 Mar; 31(3):369-76. PubMed ID: 21083802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of radiotherapy plus erlotinib versus chemoradiotherapy for elderly patients with esophageal cancer: a propensity score-matched analysis.
    Song T; Du D; Zhang X; Fang M; Wu S
    Dis Esophagus; 2017 Sep; 30(9):1-10. PubMed ID: 28859362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy.
    Korpics MC; Block AM; Martin B; Hentz C; Gaynor ER; Henry E; Harkenrider MM; Solanki AA
    Cancer; 2017 Sep; 123(18):3524-3531. PubMed ID: 28581675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent chemoradiotherapy shows long-term survival after conversion from locally advanced to resectable hepatocellular carcinoma.
    Lee IJ; Kim JW; Han KH; Kim JK; Kim KS; Choi JS; Park YN; Seong J
    Yonsei Med J; 2014 Nov; 55(6):1489-97. PubMed ID: 25323884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion.
    Onishi H; Nouso K; Nakamura S; Katsui K; Wada N; Morimoto Y; Miyahara K; Takeuchi Y; Kuwaki K; Yasunaka T; Miyake Y; Shiraha H; Takaki A; Kobayashi Y; Sakaguchi K; Kanazawa S; Yamamoto K
    Hepatol Int; 2015 Jan; 9(1):105-12. PubMed ID: 25788384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined resection and radiofrequency ablation versus transarterial embolization for intermediate-stage hepatocellular carcinoma: A propensity score matching study.
    Espinosa W; Liu YW; Wang CC; Lin CC; Wang JH; Lu SN; Hung CH
    J Formos Med Assoc; 2018 Mar; 117(3):197-203. PubMed ID: 28411877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.